Cytokinetics director granted stock and options
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director Robert Arthur Harrington received equity compensation in the form of common stock and stock options. He was granted 2,851 shares of common stock and now holds 21,781 shares directly.
He was also granted 4,301 non-qualified stock options exercisable at $77.15 per share, expiring on May 26, 2036, linked to 4,301 shares of common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (Right to Buy) | 4,301 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 2,851 | $0.00 | $0.00 |
Key Figures
Key Terms
Non-Qualified Stock Option (Right to Buy) financial
transaction code A financial
grant/award acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did CYTK director Robert Harrington report on this Form 4?
What are the terms of Robert Harrington’s new Cytokinetics stock options?
Does the CYTK Form 4 show any derivative exercises by Robert Harrington?
AI-generated analysis. How Rhea-AI works. Not financial advice.